Compare CACC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CACC | GKOS |
|---|---|---|
| Founded | 1972 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.4B |
| IPO Year | 1992 | 2015 |
| Metric | CACC | GKOS |
|---|---|---|
| Price | $463.42 | $115.92 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $465.00 | $125.54 |
| AVG Volume (30 Days) | 104.4K | ★ 865.8K |
| Earning Date | 01-29-2026 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.44 | N/A |
| EPS | ★ 37.89 | N/A |
| Revenue | ★ $1,232,900,000.00 | $469,820,000.00 |
| Revenue This Year | $129.15 | $31.15 |
| Revenue Next Year | $1.97 | $24.15 |
| P/E Ratio | $12.21 | ★ N/A |
| Revenue Growth | ★ 45.72 | 30.38 |
| 52 Week Low | $401.90 | $73.16 |
| 52 Week High | $560.00 | $163.71 |
| Indicator | CACC | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 76.42 |
| Support Level | $454.14 | $105.88 |
| Resistance Level | $485.00 | $116.72 |
| Average True Range (ATR) | 14.70 | 3.26 |
| MACD | 0.09 | 0.07 |
| Stochastic Oscillator | 39.55 | 94.61 |
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.